• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022 - Product Image

PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022

  • Published: February 2013
  • Region: France
  • 130 pages
  • GlobalData

PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022”. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer’s Dilantin, Abbott’s Depakote, and Novartis’ Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline’s Trobalt/Potiga and Eisai’s Fycompa which both offer first-in-class mechanisms READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Classification of Seizures
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.2.3 Prognosis
3.2.4 Quality of Life
4 Disease Management
4.1 Diagnosis
4.2 Treatment Guidelines
4.3 Clinical Practice
4.4 France
4.4.1 Diagnosis
4.4.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles – Major Brands
5.3.1 Keppra (levetiracetam)
5.3.2 Lamictal (lamotrigine)
5.3.3 Lyrica (pregabalin)
5.3.4 Vimpat (lacosamide)
5.3.5 Zonegran (zonisamide)
5.3.6 Banzel/Inovelon (rufinamide)
5.3.7 Trobalt/Potiga (retigabine/ezogabine)
5.3.8 Zebinix (eslicarbazepine acetate)
5.3.9 Fycompa (perampanel)
5.3.10 Older-Generation AEDs
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Refractory Epilepsy
6.2.2 Safety/Side Effect Profiles
6.2.3 Curative/Disease-Modifying Agents
6.2.4 Predictive Tools and Need for More Directed Treatments
6.2.5 Improved Preclinical Models and Clinical Trial Paradigms
6.2.6 Treatment Gap
6.3 Unmet Needs Gap Analysis
6.4 Opportunities
6.4.1 Disease-Modifying Agents
6.4.2 Improved Preclinical Models and Clinical Trial Paradigms
6.4.3 Treatment Gap
7 Pipeline Assessment
7.1 Overview
7.2 Strategic Pipeline Assessment
7.3 Pipeline by Phases of Development
7.3.1 Phase III Pipeline
7.3.2 Phase III Pipeline – Reformulations/New Delivery Systems
7.3.3 Phase IIb Pipeline
7.3.4 Phase II Pipeline
7.3.5 Phase I Pipeline
7.3.6 Preclinical Pipeline
7.3.7 Discovery Pipeline
7.4 Pipeline by Mechanism of Action
7.5 Promising Drugs in Clinical Development
7.5.1 Brivaracetam
7.5.2 Ganaxolone
7.5.3 VX-765
8 Market Outlook
8.1 France
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Prevalent Epilepsy Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class Based on MOA
9.4.4 Launch Dates and Patent and Market Exclusivity Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About Us
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables
Table 1: Epilepsy Syndromes by Age at Onset (2009 ILAE Classification)
Table 2: Classification of Seizures
Table 3: Etiology of Epilepsy According to Age
Table 4: Etiology of Partial Seizures
Table 5: Etiology of Generalized Seizures
Table 6: Some of the Genes Involved in Epilepsy
Table 7: Summary of Diagnostic Tools for Epilepsy
Table 8: Treatment Guidelines for Epilepsy
Table 9: AED Options by Seizure Type
Table 10: Top Three AEDs Prescribed for Epilepsy by Market
Table 11: Types of Epilepsy Surgery
Table 12: France, Epilepsy Patient Referrals to Neurologist
Table 13: France, Most-Prescribed First-Line and Second-Line AEDs
Table 14: Leading Treatments for Epilepsy, 2012
Table 15: Product Profile – Keppra
Table 16: Keppra SWOT Analysis, 2012
Table 17: Product Profile – Lamictal
Table 18: Lamictal SWOT Analysis, 2012
Table 19: Product Profile – Lyrica
Table 20: Lyrica SWOT Analysis, 2012
Table 21: Product Profile – Vimpat
Table 22: Vimpat SWOT Analysis, 2012
Table 23: Product Profile – Zonegran
Table 24: Zonegran SWOT Analysis, 2012
Table 25: Product Profile – Banzel/Inovelon
Table 26: Banzel/Inovelon SWOT Analysis, 2012
Table 27: Product Profile – Trobalt/Potiga
Table 28: Trobalt/Potiga SWOT Analysis, 2012
Table 29: Product Profile – Zebinix
Table 30: Zebinix SWOT Analysis, 2012
Table 31: Product Profile – Fycompa
Table 32: Fycompa SWOT Analysis, 2012
Table 33: Summary of Minor Drug Classes, 2012
Table 34: Overall Unmet Needs – Current Level of Attainment
Table 35: Clinical Unmet Needs – Gap Analysis, 2012
Table 36: Epilepsy – Phase III Pipeline, 2012
Table 37: Epilepsy – Phase III Pipeline (Reformulations), 2012
Table 38: Epilepsy – Phase IIb Pipeline, 2012
Table 39: Epilepsy – Phase II Pipeline, 2012
Table 40: Epilepsy – Phase I Pipeline, 2012
Table 41: Epilepsy – Preclinical Pipeline, 2012
Table 42: Epilepsy - Discovery Pipeline, 2012
Table 43: Comparison of MOA of Drugs in Development for Epilepsy, 2012
Table 44: Epilepsy – Promising Drugs in Clinical Development
Table 45: Product Profile – Brivaracetam
Table 46: Brivaracetam SWOT Analysis, 2012
Table 47: Product Profile – Ganaxolone
Table 48: Ganaxolone SWOT Analysis, 2012
Table 49: Product Profile – VX-765
Table 50: VX-765 SWOT Analysis, 2012
Table 51: Sales Forecasts ($m) for Epilepsy in France, 2012–2022
Table 52: Key Events Impacting Sales for Epilepsy in France, 2012–2022
Table 53: Epilepsy Market in France – Drivers and Barriers, 2012–2022
Table 54: Key Launch Dates
Table 55: Key Patent Expiries and Market Exclusivity Expiries-
Table 56: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation
Figure 2: Mechanisms of Action of AEDs at the Synapse
Figure 3: AED Selection Based on Comorbidity
Figure 4: Epilepsy – Pipeline by MOA, 2012
Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Epilepsy, 2012–2022
Figure 6: Sales for Epilepsy in France by Drug Class, 2012–2022

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos